Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 3/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.44 |
| ▸ | GABRP | O00591 | 2/20 | 0.42 |
| ▸ | GABRD | O14764 | 2/20 | 0.42 |
| ▸ | G6PD | P11413 | 2/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.42 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.42 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.42 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.42 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.42 |
| ▸ | GABRE | P78334 | 2/20 | 0.42 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.42 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.42 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.42 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL518237 | 1.00 | SRD5A2 (0.46) | SRD5A2ARSRD5A1GABRPGABRD | |
| SCHEMBL8380414 | 0.88 | SRD5A2 (0.45) | SRD5A2GABRPGABRDG6PDGABRA1 | |
| SCHEMBL8014771 | 0.88 | SRD5A2 (0.45) | SRD5A2GABRPGABRDG6PDGABRA1 | |
| SCHEMBL9665439 | 0.80 | SRD5A2 (0.51) | SRD5A2ARSRD5A1LMNABLM | |
| SCHEMBL9665450 | 0.80 | SRD5A2 (0.51) | SRD5A2ARSRD5A1LMNABLM | |
| SCHEMBL9853139 | 0.79 | SRD5A2 (0.40) | SRD5A2ARSRD5A1 | |
| SCHEMBL3869928 | 0.78 | SRD5A1 (0.38) | SRD5A2SRD5A1KMT2A | |
| SCHEMBL3869935 | 0.78 | SRD5A1 (0.38) | SRD5A2SRD5A1KMT2A | |
| SCHEMBL15121547 | 0.78 | SRD5A1 (0.38) | SRD5A2SRD5A1KMT2A | |
| SCHEMBL13844000 | 0.77 | SRD5A2 (0.73) | SRD5A2ARSRD5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2414378-B1 | SEPARATION OF 4-AZA-ANDROST-1-ENE-17-OIC ACID FROM 4-AZA-ANDROSTAN-17-OIC ACID | PHF SA (CH) | 2014-03-05 | — | — | EP | claimed |
| US-8664395-B2 | Purification 4-aza-androst-1-ene-17-oic acid from 4-aza-androstan-17-oic acid | PHF S.A. (CH) | 2014-03-04 | — | — | US | claimed |
| EP-2414378-A1 | PURIFICATION 4-AZA-ANDROST-1-ENE-17-OIC ACID FROM 4-AZA-ANDROSTAN-17-OIC ACID | PHF SA (CH) | 2012-02-08 | — | — | EP | claimed |
| US-20120029196-A1 | PURIFICATION 4-AZA-ANDROST-1-ENE-17-OIC ACID FROM 4-AZA-ANDROSTAN-17-OIC ACID | PHF S.A. (CH) | 2012-02-02 | — | — | US | claimed |
| WO-2010112079-A1 | PURIFICATION 4-AZA-ANDROST-1-ENE-17-OIC ACID FROM 4-AZA-ANDROSTAN-17-OIC ACID | PHF S.A. (CH) | 2010-10-07 | — | — | WO | claimed |
| EP-2414378-B1 | SEPARATION OF 4-AZA-ANDROST-1-ENE-17-OIC ACID FROM 4-AZA-ANDROSTAN-17-OIC ACID | PHF SA (CH) | 2014-03-05 | — | — | EP | disclosed |
| US-8664395-B2 | Purification 4-aza-androst-1-ene-17-oic acid from 4-aza-androstan-17-oic acid | PHF S.A. (CH) | 2014-03-04 | — | — | US | disclosed |
| US-8664395-B2 | Purification 4-aza-androst-1-ene-17-oic acid from 4-aza-androstan-17-oic acid | PHF S.A. (CH) | 2014-03-04 | — | — | US | disclosed |
| US-8664395-B2 | Purification 4-aza-androst-1-ene-17-oic acid from 4-aza-androstan-17-oic acid | PHF S.A. (CH) | 2014-03-04 | — | — | US | disclosed |
| EP-2414378-A1 | PURIFICATION 4-AZA-ANDROST-1-ENE-17-OIC ACID FROM 4-AZA-ANDROSTAN-17-OIC ACID | PHF SA (CH) | 2012-02-08 | — | — | EP | disclosed |
| EP-2414378-A1 | PURIFICATION 4-AZA-ANDROST-1-ENE-17-OIC ACID FROM 4-AZA-ANDROSTAN-17-OIC ACID | PHF SA (CH) | 2012-02-08 | — | — | EP | disclosed |
| US-20120029196-A1 | PURIFICATION 4-AZA-ANDROST-1-ENE-17-OIC ACID FROM 4-AZA-ANDROSTAN-17-OIC ACID | PHF S.A. (CH) | 2012-02-02 | — | — | US | disclosed |
| US-20120029196-A1 | PURIFICATION 4-AZA-ANDROST-1-ENE-17-OIC ACID FROM 4-AZA-ANDROSTAN-17-OIC ACID | PHF S.A. (CH) | 2012-02-02 | — | — | US | disclosed |
| WO-2010112079-A1 | PURIFICATION 4-AZA-ANDROST-1-ENE-17-OIC ACID FROM 4-AZA-ANDROSTAN-17-OIC ACID | PHF S.A. (CH) | 2010-10-07 | — | — | WO | disclosed |
| WO-2010112079-A1 | PURIFICATION 4-AZA-ANDROST-1-ENE-17-OIC ACID FROM 4-AZA-ANDROSTAN-17-OIC ACID | PHF S.A. (CH) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029196-A1 | PURIFICATION 4-AZA-ANDROST-1-ENE-17-OIC ACID FROM 4-AZA-ANDROSTAN-17-OIC ACID | NR5A1, SRD5A2, CYP19A1 | SRD5A2 2/4885AR 19/4885SRD5A1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.